NCT07053423View on ClinicalTrials.gov

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

PHASE4RecruitingINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

December 23, 2028

Study Completion Date

February 15, 2029

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Dupilumab

Pharmaceutical form:Solution for injection-Route of administration:SC injection

DRUG

Placebo

Pharmaceutical form:Solution for injection-Route of administration:SC injection

Trial Locations (5)

33126

RECRUITING

Finlay Medical Research- Site Number : 8400010, Miami

51092

RECRUITING

Investigational Site Number : 2500004, Reims

LE3 9QP

RECRUITING

Investigational Site Number : 8260003, Leicester

BD9 6DA

RECRUITING

Investigational Site Number : 8260001, Bradford

NE1 4LP

RECRUITING

Investigational Site Number : 8260006, Newcastle upon Tyne

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY